ALXO Alx Oncology Holdings Inc

Price (delayed)

$14.38

Market cap

$585.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.72

Enterprise value

$519.56M

ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ...

Highlights
The EPS has dropped by 127% year-on-year and by 18% since the previous quarter
ALXO's net income has dropped by 86% year-on-year and by 18% since the previous quarter

Key stats

What are the main financial stats of ALXO
Market
Shares outstanding
40.75M
Market cap
$585.94M
Enterprise value
$519.56M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.85
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$110.47M
EBITDA
-$110.29M
Free cash flow
-$81.52M
Per share
EPS
-$2.72
Free cash flow per share
-$2
Book value per share
$7.78
Revenue per share
$0
TBVPS
$8.5
Balance sheet
Total assets
$346.02M
Total liabilities
$29.7M
Debt
$0
Equity
$316.32M
Working capital
$292.9M
Liquidity
Debt to equity
0
Current ratio
13.23
Quick ratio
13.08
Net debt/EBITDA
0.6
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-29.7%
Return on equity
-31.4%
Return on invested capital
-98.6%
Return on capital employed
-34.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALXO stock price

How has the Alx Oncology Holdings stock price performed over time
Intraday
-1.64%
1 week
12.43%
1 month
38.8%
1 year
-79%
YTD
-33.09%
QTD
77.75%

Financial performance

How have Alx Oncology Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$111.58M
Net income
-$110.46M
Gross margin
N/A
Net margin
N/A
ALXO's operating income has shrunk by 92% YoY and by 19% QoQ
ALXO's net income has dropped by 86% year-on-year and by 18% since the previous quarter

Growth

What is Alx Oncology Holdings's growth rate over time

Valuation

What is Alx Oncology Holdings stock price valuation
P/E
N/A
P/B
1.85
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 127% year-on-year and by 18% since the previous quarter
The price to book (P/B) is 43% less than the last 4 quarters average of 3.3
Alx Oncology Holdings's equity has decreased by 22% YoY and by 8% QoQ

Efficiency

How efficient is Alx Oncology Holdings business performance
ALXO's return on equity has dropped by 97% year-on-year and by 25% since the previous quarter
The return on assets has dropped by 92% year-on-year and by 24% since the previous quarter
ALXO's return on invested capital has surged by 50% since the previous quarter

Dividends

What is ALXO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALXO.

Financial health

How did Alx Oncology Holdings financials performed over time
The total liabilities has surged by 82% year-on-year and by 48% since the previous quarter
The quick ratio has dropped by 55% year-on-year and by 37% since the previous quarter
The debt is 100% smaller than the equity
Alx Oncology Holdings's equity has decreased by 22% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.